Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of JNJ-81201887 for geographic atrophy secondary to age-related macular degeneration
2022-500747-21-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2025
- Modality
- Gene Therapies
- Countries
- 17
01
Overview
Phase 2, open-label trial of JNJ-81201887 in age-related macular degeneration (AMD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Ocular and systemic treatment-emergent adverse events, Clinical laboratory and safety assessments and 1 more. Planned start Feb 2025; status: authorised.
02
Drugs
JNJ-81201887
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2022-500747-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500747-21-00.